SEI Investments’s Zentalis Pharmaceuticals ZNTL Stock Holding History

SEI Investments’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$448K	Buy	191,551 +24,451	+15%	+$63.1K	﹤0.01%	2691
2025 Q4	$226K	Hold	167,100	–	–	﹤0.01%	2848
2025 Q3	$252K	Hold	167,100	–	–	﹤0.01%	2532
2025 Q2	$194K	Sell	167,100 -35,320	-17%	-$46.6K	﹤0.01%	2575
2025 Q1	$322K	Buy	202,420 +167,100	+473%	+$360K	﹤0.01%	2311
2024 Q4	$107K	Buy	+35,320	New	+$116K	﹤0.01%	2569
2023 Q2	–	Sell	-74,794	Closed	-$1.29M	–	2771
2023 Q1	$1.29M	Buy	+74,794	New	+$1.51M	﹤0.01%	1786
2022 Q4	–	Sell	-74,192	Closed	-$1.61M	–	2691
2022 Q3	$1.61M	Sell	74,192 -1,866	-2%	-$51K	﹤0.01%	1631
2022 Q2	$2.14M	Buy	+76,058	New	+$2.01M	﹤0.01%	1528

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

SEI Investments's ZNTL Position: Q1 2026 in Review

SEI Investments increased its Zentalis Pharmaceuticals (ZNTL) stake by 15% in Q1 2026, buying an estimated $63.1K and bringing the position to 191,551 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

SEI Investments first reported a position in ZNTL in Q2 2022 and has held it in 9 quarters since. The position peaked at $2.14M in Q2 2022. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

SEI Investments held 191,551 shares of Zentalis Pharmaceuticals worth $448K as of Q1 2026.
SEI Investments bought 24,451 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $63.1K.
Zentalis Pharmaceuticals made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2691 holding.
SEI Investments first reported a position in Zentalis Pharmaceuticals in Q2 2022 and has held it in 9 quarters since.
SEI Investments's Zentalis Pharmaceuticals position peaked at $2.14M in Q2 2022.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.